BioCentury
ARTICLE | Clinical News

Hearing loss trial of GenVec gene therapy clears hurdle

May 3, 2016 1:35 AM UTC

GenVec Inc. (NASDAQ:GNVC) rose $0.02 to $0.80 on Monday after partner Novartis AG (NYSE:NVS; SIX:NOVN) told the biotech a DSMB recommended continuing a Phase I/II of gene therapy CGF166 to treat hearing loss. On Jan. 11, GenVec lost $1.02 (59%) to $0.72 after it said Novartis would pause enrollment in the study to conduct a per-protocol safety review (see BioCentury Extra, Jan. 11).

GenVec said it expects enrollment to resume "in the coming months," and that the study will be completed in 2017. ...